Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.95)
# 2,961
Out of 4,732 analysts
47
Total ratings
29.41%
Success rate
-2.16%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $2.12 | +135.85% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.09 | +288.35% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.20 | +181.25% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $9.33 | -3.54% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.96 | +733.33% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $9.88 | +61.94% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $12.17 | +6.82% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $1.98 | +354.55% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $6.01 | +33.11% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $3.76 | +86.17% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.63 | +329.45% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.31 | +663.36% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.45 | +2,795.32% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $32.64 | +80.76% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $121.18 | +48.54% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.98 | +2,155.48% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.66 | +145.90% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.47 | +8.59% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $5.64 | +390,199.29% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $33.35 | -34.03% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $3.30 | +21,718.18% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $58.46 | -31.58% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $6.38 | +4,837.30% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $37.59 | +33.01% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $2.12
Upside: +135.85%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $3.09
Upside: +288.35%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.20
Upside: +181.25%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $9.33
Upside: -3.54%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.96
Upside: +733.33%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $9.88
Upside: +61.94%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $12.17
Upside: +6.82%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $1.98
Upside: +354.55%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $6.01
Upside: +33.11%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $3.76
Upside: +86.17%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $1.63
Upside: +329.45%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $1.31
Upside: +663.36%
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $0.45
Upside: +2,795.32%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $32.64
Upside: +80.76%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $121.18
Upside: +48.54%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.98
Upside: +2,155.48%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $3.66
Upside: +145.90%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.47
Upside: +8.59%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $5.64
Upside: +390,199.29%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $33.35
Upside: -34.03%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $3.30
Upside: +21,718.18%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $58.46
Upside: -31.58%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $6.38
Upside: +4,837.30%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $37.59
Upside: +33.01%